|
US7563874B2
(en)
*
|
1998-08-31 |
2009-07-21 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
MXPA02000962A
(es)
*
|
1999-07-29 |
2002-07-02 |
Medarex Inc |
Anticuerpos monoclonales humanos para her2/neu.
|
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
|
CA2798625C
(en)
|
2000-04-17 |
2017-01-24 |
Dyax Corp. |
Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
|
|
CA2407556C
(en)
|
2000-05-19 |
2011-06-21 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
WO2002061071A2
(en)
|
2000-12-18 |
2002-08-08 |
Dyax Corp. |
Focused libraries of genetic packages
|
|
ITRM20010408A1
(it)
*
|
2001-07-10 |
2003-01-10 |
Univ Napoli Federico Ii |
Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
|
|
US20050037061A1
(en)
*
|
2001-07-25 |
2005-02-17 |
Saiko Hosokawa |
Remedies for mammary cancer
|
|
EP1539235A2
(en)
|
2002-07-01 |
2005-06-15 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
|
US6987270B2
(en)
|
2003-05-07 |
2006-01-17 |
General Electric Company |
Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
|
|
ES2321841T3
(es)
|
2003-08-26 |
2009-06-12 |
Smithkline Beecham Corporation |
Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones.
|
|
EP1708750A1
(en)
*
|
2003-11-28 |
2006-10-11 |
Mitra Medical AB |
Targeting of erb antigens
|
|
LT3173073T
(lt)
|
2004-05-03 |
2025-01-10 |
Ipsen Biopharm Ltd. |
Liposomos, skirtos vaistų pristatymui
|
|
CA2582242A1
(en)
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
EP2153848A3
(en)
*
|
2005-01-27 |
2010-07-21 |
The Regents of the University of California |
Therapeutic monoclonal antibodies that neutralize botulinium neurotoxins
|
|
GB0503546D0
(en)
*
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
US8350011B2
(en)
*
|
2006-08-04 |
2013-01-08 |
Medimmune Limited |
Antibodies to ErbB2
|
|
ES2348343T3
(es)
|
2006-12-12 |
2010-12-03 |
Morphosys Ag |
Internalización.
|
|
SI2132573T1
(sl)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
|
|
WO2009008916A2
(en)
|
2007-03-22 |
2009-01-15 |
The Regents Of The University Of Californina |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US20090175784A1
(en)
|
2007-05-11 |
2009-07-09 |
Joshua Goldstein |
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US12529164B2
(en)
|
2007-09-14 |
2026-01-20 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
WO2009114815A1
(en)
|
2008-03-13 |
2009-09-17 |
Dyax Corp |
Libraries of genetic packages comprising novel hc cdr3 designs
|
|
JP5780951B2
(ja)
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のｈｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計、ならびに新規のｌｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計を含む、遺伝子パッケージのライブラリ
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US9000131B2
(en)
*
|
2008-07-31 |
2015-04-07 |
The Regents Of The University Of California |
Antibodies that neutralize botulinum neurotoxins
|
|
WO2010051502A2
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
CN102884084B
(zh)
*
|
2010-03-04 |
2016-12-07 |
西福根有限公司 |
抗her2抗体及组合物
|
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
KR102318383B1
(ko)
|
2010-07-16 |
2021-10-27 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
US9243057B2
(en)
|
2010-08-31 |
2016-01-26 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
AU2011338487B2
(en)
|
2010-12-06 |
2016-12-22 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
WO2013043864A1
(en)
*
|
2011-09-23 |
2013-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to endothelial targeting
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
BR112014012979A2
(pt)
|
2011-11-30 |
2020-10-20 |
Genentech, Inc. |
mutações erbb3 em câncer
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
WO2013192294A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
|
WO2014089127A1
(en)
|
2012-12-03 |
2014-06-12 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating her2-positive cancers
|
|
US10519247B2
(en)
*
|
2013-11-01 |
2019-12-31 |
Board Of Regents,The University Of Texas System |
Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
|
|
SG11201608192SA
(en)
|
2014-04-11 |
2016-10-28 |
Medimmune Llc |
Bispecific her2 antibodies
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
WO2016022723A1
(en)
|
2014-08-05 |
2016-02-11 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
CN107405382A
(zh)
|
2015-02-06 |
2017-11-28 |
加利福尼亚大学董事会 |
用于改善认知的方法和组合物
|
|
CN107614762B
(zh)
*
|
2015-02-24 |
2022-08-05 |
台湾地区“中央研究院” |
一种由噬菌体表达的单链变异片段抗体库
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
JP7042739B2
(ja)
|
2015-08-20 |
2022-03-28 |
イプセン バイオファーム リミティド |
癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
|
|
TW202400181A
(zh)
|
2015-08-21 |
2024-01-01 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
|
|
EP4647126A3
(en)
|
2015-10-16 |
2026-02-11 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
IL260021B
(en)
|
2015-12-14 |
2022-09-01 |
Macrogenics Inc |
Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
|
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
|
CN110402163A
(zh)
|
2016-11-02 |
2019-11-01 |
易普森生物制药有限公司 |
使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
AU2018224094B2
(en)
|
2017-02-24 |
2025-04-17 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
JP7337079B2
(ja)
|
2018-02-15 |
2023-09-01 |
マクロジェニクス，インコーポレーテッド |
変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
|
|
US20220118060A1
(en)
|
2019-02-04 |
2022-04-21 |
The Regents Of The University Of California |
Exercise-induced circulatory factors for amelioration of cognitive, neurological, and regenerative dysfunction during aging
|
|
EP4103223A4
(en)
|
2020-02-12 |
2024-05-29 |
The Regents of the University of California |
PLATELET FACTORS AND COGNITIVE IMPROVEMENT
|
|
IL295434A
(en)
|
2020-02-21 |
2022-10-01 |
Macrogenics Inc |
cd137 binding molecules and their uses
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
US12428457B2
(en)
|
2021-01-29 |
2025-09-30 |
University Of South Florida |
Cold-shock protein scaffold for engineering non-antibody binding proteins
|
|
WO2024092238A1
(en)
|
2022-10-28 |
2024-05-02 |
Unity Biotechnology, Inc. |
Klotho polypeptide or polynucleotide for improving cognition
|
|
EP4414386A1
(en)
|
2023-02-09 |
2024-08-14 |
Mariangela Figini |
Method of chemical synthesis of single-chain antibody fragments and products thereby obtained
|
|
NL2038054B1
(en)
|
2024-06-25 |
2026-01-15 |
Academisch Ziekenhuis Leiden |
A method for preparing liposomes
|